Candel Therapeutics (CADL) vs Tevogen (TVGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Candel Therapeutics (CADL) has outperformed Tevogen (TVGN) over the past year, gaining 10.8% versus a loss of 73.8%. Tevogen is the larger company by market cap ($405.2 million vs $395.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CADL | TVGN |
|---|---|---|
| Share price | $5.04 | $5.90 |
| Market cap | $395.37M | $405.20M |
| 1-day change | -1.75% | -6.35% |
| YTD return | -10.80% | -64.35% |
| 1-year return | +10.77% | -73.84% |
| 5-year return | -48.47% | — |
| EPS (TTM) | $-1.53 | $-7.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-38.18M | $-26.28M |
| 52-week high | $14.00 | $24.90 |
| 52-week low | $4.35 | $3.64 |
| Distance from 52-week high | -64.00% | -76.31% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +250.60% | — |
| Average volume | 1.26M | 7.94K |
| Shares outstanding | 78.45M | 68.68M |
| Employees | 55 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CADL has outperformed TVGN by 84.6 percentage points over the past year.
About Candel Therapeutics
CADL stock →Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees
About Tevogen
TVGN stock →Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
CADL vs TVGN FAQ
Which is bigger, Candel Therapeutics or Tevogen?
Tevogen (TVGN) is larger, with a market capitalization of $405.20M compared with $395.37M for Candel Therapeutics (CADL).
Which stock has performed better over the past year, CADL or TVGN?
CADL returned +10.77% over the past 12 months, compared with -73.84% for TVGN (price return, excluding dividends). Past performance does not predict future results.
Are Candel Therapeutics and Tevogen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.